Rheumatology
Conference Coverage
Intensive gout treatment meets urate goal, lowers tophi burden
A randomized trial of therapy to intensively lower urate for patients with gout showed benefits in meeting serum urate goal, tophus size, and...
Conference Coverage
Denosumab may halt erosive hand OA progression
In a randomized clinical trial, denosumab seemed to halt progression of erosive hand osteoarthritis, but had a delayed impact on pain.
Conference Coverage
Randomized trial finds community-based weight-loss programs ease knee OA pain
Participants who dieted and exercised in a community-based randomized trial had reductions in knee pain at 18 months; controls also improved...
Conference Coverage
StopRA trial: Hydroxychloroquine doesn’t prevent or delay onset of rheumatoid arthritis
A randomized clinical trial found that hydroxychloroquine was no more effective than placebo at preventing or delaying onset of rheumatoid...
Conference Coverage
Prednisone, colchicine equivalent in efficacy for CPP crystal arthritis
In an open-label, randomized trial, one in five patients on colchicine had diarrhea, tipping the safety scales in favor of prednisone.
Conference Coverage
NSAIDs for spondyloarthritis may affect time to conception
“If a woman is requiring regular NSAIDs for symptom control, the results of this study might encourage me to consider a biologic agent sooner to...
Conference Coverage
Combination therapy may boost remission in JIA
Study shows early methotrexate plus a biologic may aid remission and disease inactivity in pediatric polyarticular juvenile idiopathic arthritis...
Guidelines
First recommendations for cancer screening in myositis issued
The guideline, based on data from a systematic review and meta-analysis and on consensus from an international team of experts and patients,...
Guidelines
ACR introduces guideline for integrative interventions in RA
The range of recommended interventions highlighted the multidisciplinary nature of rheumatoid arthritis disease management.
Feature
In rheumatoid arthritis, reducing inflammation reduces dementia risk
Compared with conventional synthetic disease-modifying antirheumatic drugs, biologic/targeted synthetic DMARDS lower dementia risk.
From the Journals
Therapeutic drug monitoring pays off for arthritis patients
Patients who reduced their dosage of TNF-alpha inhibitor had less treatment failure and similar risk of adverse events, compared with standard...